




- (51) **International Patent Classification:**
C07K 16/28 (2006.01)
- (21) **International Application Number:**
PCT/GB2021/052495
- (22) **International Filing Date:**
24 September 2021 (24.09.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
2015115.5 24 September 2020 (24.09.2020) GB
- (71) **Applicant: IMPERIAL COLLEGE INNOVATIONS LIMITED** [GB/GB]; Level 1 Faculty Building, C/O Imperial College, Exhibition Road, London SW7 2AZ (GB).
- (72) **Inventors: HOPLEY, Stephanie;** Apollo Therapeutics Limited, 24 Hills Road, Cambridge CB2 1JP (GB). **HAMBLIN, Paul;** Apollo Therapeutics Limited, 24 Hills Road, Cambridge CB2 1JP (GB). **WILKINS, Martin;** Level 1 Faculty Building, C/O Imperial College, Exhibition Road, London SW7 2AZ (GB). **ZHAO, Lan;** Level 1 Faculty Building, C/O Imperial College, Exhibition Road, London SW7 2AZ (GB).
- (74) **Agent: HUTTER, Anton;** Venner Shipley LLP, The Surrey Research Park, 5 Stirling House, Stirling Road, Guildford Surrey GU2 7RF (GB).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
- (54) **Title:** ZIP12 ANTIBODY

Figure 10



- (57) **Abstract:** The invention relates to ZIP12 antibodies. The invention extends to compositions comprising the antibodies, including pharmaceutical compositions and kits. The invention also extends to methods of making and using the antibodies, for example in therapy and diagnosis of hypoxia-related diseases, such as pulmonary hypertension and cancer.

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*